Mersana Therapeutics, Inc. stock is up 38.66% since 30 days ago. The next earnings date is Feb 27, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 6 December’s closed higher than November.
Mersana Therapeutics, Inc. develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for ovarian cancer and NSCLC adenocarcinoma.